External organizationBristol-Myers Squibb GmbH & Co. KGaA (BMS)

Basic data

Name:

Bristol-Myers Squibb GmbH & Co. KGaA

Acronym:

BMS

Country:

Germany

Region/province:

Bayern

City:

München

URL:

www.b-ms.de

Projects

ATTICUS Amendment B – Apixaban for treatment of embolic stroke of undetermined source

2017 - 2021

Bristol-Myers Squibb GmbH & Co. KGaA (BMS)

ATTICUS Amendment C – Apixaban for treatment of embolic stroke of undetermined source

2021 - 2022

Bristol-Myers Squibb GmbH & Co. KGaA (BMS)

Axiomatic - BMS – A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Response-Adaptive Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

2019 - 2021

Bristol-Myers Squibb GmbH & Co. KGaA (BMS)

2016 - 2019

Bristol-Myers Squibb GmbH & Co. KGaA (BMS)

Studie CA209-429

2016 - 2018

Bristol-Myers Squibb GmbH & Co. KGaA (BMS)

Help

will be deleted permanently. This cannot be undone.